CD274 and hepatocellular carcinoma: Additionally, ICIs targeting PD-1, PD-L1, or CTLA4 have enabled the possibility of long-term survival in patients with tumors such as melanoma, HCC, breast cancer, and colorectal cancer (47, 48).